Accretropin and Perforomist, Symbicort

• Generic Name: somatropin
• Dosage Forms: n.a.
• Other Brand Names: Genotropin, Humatrope, Norditropin FlexPro Pen, Nutropin AQ NuSpin 10, Nutropin AQ Pen 10 Cartridge, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive, Genotropin Miniquick, Norditropin Nordiflex Pen, Tev-Tropin, Nutropin, Norditropin, Nutropin AQ, Nutropin Depot, Norditropin Cartridge, Saizen Click-Easy, Omnitrope Pen 5 Cartridge, HumatroPen, Omnitrope Pen 10 Cartridge, Nutropin AQ Pen 20 Cartridge, Nutropin AQ NuSpin 5, Nutropin AQ NuSpin 20, Saizen Kit

Accretropin is a form of human growth hormone.

Accretropin is used to treat growth failure in children who lack natural growth hormone. Accretropin is also used for the treatment of short stature associated with Turner Syndrome in children.

• Generic Name: formoterol
• Dosage Forms: n.a.
• Other Brand Names: Perforomist, Foradil Aerolizer, Foradil Aerolizer>

Formoterol: Used concomitantly with long-term asthma controller therapy (e.g., inhaled corticosteroids) for prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma).

Monotherapy with long-acting β2-adrenergic agonists (e.g., formoterol) increases the risk of asthma-related death and may increase the risk of asthma-related hospitalization in children and adolescents. Use of formoterol alone for treatment of asthma without concomitant use of long-term asthma controller therapy (e.g., inhaled corticosteroids) is contraindicated. (See Asthma-related Death and Serious Asthma-related Events under Cautions.)

Formoterol in fixed combination with budesonide or mometasone (formoterol/budesonide, formoterol/mometasone): Treatment of asthma only in patients not responding adequately to long-term asthma controller therapy (e.g., inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a long-acting β2-adrenergic agonist.

Once asthma control achieved and maintained, assess patient at regular intervals and step down therapy (e.g., discontinue formoterol or formoterol/budesonide) if possible without loss of asthma control, and maintain patient on long-term asthma controller therapy (e.g., inhaled corticosteroids).

Do not use formoterol/budesonide in patients with asthma adequately controlled on low or medium dosage of inhaled corticosteroids.

Formoterol alone or in fixed combination with budesonide or mometasone not indicated for relief of acute bronchospasm; do not initiate in patients with rapidly deteriorating or potentially life-threatening episodes of asthma. (See Acute Exacerbations of Asthma or COPD under Cautions.)

Formoterol, formoterol/budesonide, or formoterol in fixed combination with glycopyrrolate (formoterol/glycopyrrolate): Long-term maintenance treatment of bronchospasm or airflow obstruction associated with COPD, including chronic bronchitis and emphysema.

Do not initiate formoterol alone or in fixed combination with budesonide or glycopyrrolate in patients with substantially worsening or acutely deteriorating COPD; do not use to treat acute symptoms. (See Acute Exacerbations of Asthma or COPD under Cautions.)

Use of long-acting β2 agonists (e.g., formoterol) with or without inhaled corticosteroids for acute exacerbations of COPD not evaluated. Use a short-acting inhaled β2-adrenergic agonist intermittently (as needed) for acute symptoms of COPD.